The University will use the PredictionBase suite to focus on the application of cheminformatics within drug discovery during training courses available to both academic and commercial organizations.
Professor Alexandre Varnek, head of the master’s courses on cheminformatics, commented: “The objective of the master’s training courses is to show best practice regarding cheminformations within drug discovery. We therefore are eager to demonstrate one of the best possible solutions relating to predictive ADME/Tox – this is why we chose PredictionBase.”
As part of the collaboration, IDBS has accepted a master’s student at its UK headquarters to help further strengthen the PredictionBase suite by working exclusively on the development and refinement of ADME/Tox predictive models.
IDBS also plans to use the facilities at the Strasbourg University to host training courses and workshops relating to IDBS’ predictive technology.
Neil Kipling, founder and CEO of IDBS, remarked: “Increasingly, organizations recognize that not all predictive solutions are the same. Our emphasis on model validation, as well as our ability to incorporate external predictive models, is seen as increasingly valuable. We are very pleased to continue our efforts in this area with a prestigious academic establishment and look forward to a long and mutually beneficial relationship.”